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by Ila L. Cote* and Steven P. Bayard*
ThispaperdiscussestheEnvironmental ProtectionAgency's (EPA) riskassessmentof1,3-butadiene. The
assessment focuses on estimation ofincreased cancer risk to populations living near industrial sources of
1,3-butadiene emissionsratherthanoccupationally exposedpopulations. Incremental cancerriskestimates
based on extrapolation from laboratory animal data are presented. Pharmacokinetic data published since
the EPA's 1985 assessment are incorporated, which somewhat alters the earlier assessment ofcancer risk.
Characterization ofemissionsources, estimatesofambientairconcentrations, andpopulationexposureare
also discussed.
The estimate presented in this paper of excess cancer cases resulting from point source exposure to
1,3-butadiene is decreased to approximately 40%o of the estimate published in 1985 from 6.4 in 10 to 2.5
chances in 10fora lifetime exposure to 1 ppm. The currentestimate is no morethan eight additional cancer
incidences in the general population. Increased risktothe most exposed individuals is not anticipated to be
greater than 1 in 10. This reduction in the risk estimate is due to a change in the estimate of 1,3-butadiene
potency (i.e., incremental unit risk estimate) based on incorporation of new pharmacokinetic data.
Background
1,3-Butadiene is acolorless gasused intheproduction
of polymers, elastomers, and other chemicals. Some
1,3-butadiene products are as follows: automobile tires,
high-impact plastic used inautomobiles, appliance parts
and pipes, and synthetic fibers. It is produced as a
coproduct in the production of ethylene, by oxidative
dehydrogenation ofn-butenes, or by dehyrogenation of
n-butanes. Automobile exhause also contains 1,3-
butadiene (1,2).
Due to its volatility, 1,3-butadiene is primarily an air
contaminant. Because of potential carcinogenic effects
associated with 1,3-butadiene exposure (3), in 1984 EPA
initiated a review to determine the potential impact on
public health from exposure to 1,3-butadiene present in
the ambient air. The results ofthis review are the topic
of this paper and are being used to determine if air
emissions of 1,3-butadiene should be regulated by EPA
under the Clean Air Act.
Hazard Identification
The first element in conducting a cancer risk as-
sessmentisthe evaluation oftheweightofevidencethat
a giveti chemical is likely to produce an adverse health
effect in humans. The effect ofgreatest emphasis inthis
assessment is cancer, both because ofthe seriousness of
the effect and because ofthe strength ofthe evidence.
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Epidemiologic studies ofthe potential health hazards
associated with 1,3-butadiene exposure arelimited. Un-
til recently the data have been considered inconclusive
and inadequate for classification or quantifying risks.
Some excess cancers ofthelymphaticandhematopoietic
tissueswere, however, seenin some studies(4-6). More
recent information (7-10) provides additional con-
firmatory evidence that 1,3-butadiene exposure is asso-
ciated with these lymphatic and hematopoietic system
cancersinhumans, butaccuratecontemporaryexposure
estimates are lacking.
Three lifetime inhalation carcinogenicity studies have
been carried out in mice and rats (3,11-14). There were
significantincreasesintheincidencesofprimarytumors
in both species, both sexes, and at multiple organ sites;
dose-responsetrendswereobservedinallthreestudies.
Therearemarkeddifferences, however, inbothaffected
tumor sites and sensitivity between exposed mice and
rats, with mice being much more sensitive. In the rat
study (14), groups ofmale and female Sprague-Dawley
rats were exposed for 2 years, 6 hr/day, 5 days/week to
0, 1000, and 8000 ppm 1,3-butadiene via inhalation.
Significantly decreased survivals were observed inboth
the male and female 8000-ppm dose groups. Increased
tumors were observed in males in Leydig cells and
pancreatic exocrine and Zymbal glands, with increases
being statistically significant only at the highest con-
centrationandonlyforthetwoformersites. Femalerats
showed increased mammary, uterine, Zymbal gland,
and thyroid gland follicular cell tumors. Other than
increases in common mammary gland tumors, response
wasgenerally lessthan 10%. Formore details see Owen
et al. (15).COTE AND BAYARD
In comparison tothe statistically significant but small
increases in rats, the cancer response, in both male and
female B6C3F1 mice, at comparatively lowerconcentra-
tions of 625 and 1250 ppm was both massive and rapid
and included as many as seven primary tumor sites
(3,12,13). Survivalinbothsexesatbothtreatmentdoses
was affected to the point where the studies had to be
terminated after 60 and 61 weeks. Early tumors, espe-
cially malignant lymphomas and hemangiosarcomas of
the heart, were responsible for most of these deaths.
Other statistically increased tumor sites included lung
and forestomach (both sexes) and liver, mammary
glands, and ovarian glands (females). [Information from
a recently completed study in B6C3F1 mice by Melnick
et al. (11) provides additional evidence ofthe carcinoge-
nicity of 1,3-butadiene at lower concentrations.]
Based on the previous evidence of positive cancer
responseintwoanimalspeciesandinadequateepidemio-
logic data, EPA in 1985 classified 1,3-butadiene as a
"probable" human carcinogen, Group B2 according to
EPA's Guidelines for Carcinogen Risk Assessment
(16,17). The authors ofthis paperbelieve that epidemio-
logic evidence provided at this symposium (8-10) will
result in an EPA reclassification upgrade for 1,3-
butadiene from Group B2 to Group Bi. The Group Bi
classification is indicative of a probable human carcino-
gen based on limited human data and sufficient animal
data. The Group B2 classification isindicative ofaprob-
able human carcinogen based on animal data only.
Dose-Response Assessment
The second element in acancerrisk assessment isthe
estimation ofthe carcinogenic potency ofthe substance
in humans, which is expressed as the "incremental unit
risk," sometimes shortened tothe"unitrisk."Theincre-
mentalunitriskestimateforanairpollutantisdefinedas
the lifetime probability of excess cancer risk, i.e., the
risk, in excess ofthe background rate, that is estimated
to occurbecause ofexposure to oneunit ofthe agent per
volume of air.
Choice of Model
Since risks at low ambient exposure levels cannot
ordinarily be estimated directly either by experiments
in laboratory animals or by epidemiologic studies, a
number ofmathematical models havebeendeveloped to
extrapolate from higher to lower exposures and from
animalstohumans. Severaldifferentextrapolationmod-
elswillusuallyfittheobserveddatareasonablywell, but
they may lead to large differences in the extrapolated
risk at low doses.
Atpresent, mechanisms ofthecarcinogenesis process
are largely unknown and data aregenerally limited. Ifa
carcinogenic agent actsbyaccelerating orenhancingthe
same carcinogenic process that leads to the background
occurrence ofcancer, the added effect ofthe carcinogen
at low doses is expected to be virtually linear (18-21);
althoughathighdosesnonlineareffectsusuallyoccur. In
theabsenceofevidencetothecontrary, EPAhaschosen
to extrapolate to low exposures using this linearity
assumption and has chosen amodelforanimal to human
extrapolation called the linearized multistage model
(22). This procedure fits the most pertinent animal data
set(s) to apolynomial ofsuitable degree and then extra-
polates to low doses using an upper-limit linear term
consistent with the data.
For each assessment the EPA reviews the available
evidence on carcinogenic mechanisms and otherbiologi-
calorstatisticalevidencethatindicatesthesuitability of
aparticularextrapolationmodel. Whenthecompound is
mutagenic, the multistage model is used as an applica-
tion of the mutation theory on cancer. When the com-
pound is a promutagen, as 1,3-butadiene appears to be,
the linearized multistage model is still appropriate; an
adjustment must be made, if possible, for the target
organ dose of the active metabolite(s).
Itshouldbeemphasizedthatthelinearizedmultistage
procedure leads to a plausible upper limit ofexcess risk
that is consistent with some proposed mechanisms of
carcinogenesis. Such an estimate, however, does not
necessarily give a realistic prediction of the low dose
risk.
Choice of Data Set
An estimate of the carcinogenic potency of 1,3-
butadiene tohumans wasmadebased onthe most sensi-
tive animal species. In this case, since the cancer re-
sponses in the male and female mice were so similar
(3-13) both sets of results were used by taking the
geometric mean of the 95% upper-limit estimates de-
rived from each sex by the use of the linearized multi-
stage model.
To derive estimates of target tissue dose, the data
fromanunpublishedstudy(23)onmalemousetotalbody
burden were used in EPA's risk assessment (17). How-
ever, following EPA's publication, additional experi-
ments and further analysis by the National Toxicology
Program (NTP) led to a publication offinal results (24)
thatdifferfromthoseintheunpublishedreport. Therisk
assessment presented at this meeting used these final
results for the body burden and absorption estimates.
Estimates of total body burden were used instead of
estimates oftarget organ dose because ofthehigh num-
ber of affected sites and the different dose and time-
response characteristics of the different tumor sites.
Incalculatinginternaldosesfromexternalexposures,
estimatesofthelow-exposureretentionof1,3-butadiene
and/or metabolites following 6-hr exposures to mice
were 20% over a two order ofmagnitude range of con-
centration (up to 7 ppm). At the higher exposures of70
and 930ppm, retention decreasedto8%and4%, respec-
tively(24). Sincemetabolic clearance of1,3-butadienein
mice (and rats) follows linear pharmacokinetics below
exposure concentrations ofabout 1000 ppm (25,26), the
decreases at high concentrations in micromoles body
burden/ppm exposure concentration after a 6-hr expo-
sure are assumed to result from decreased lungabsorp-
150CANCER RISK ASSESSMENT OF 1,3-BUTADIENE
tion. When body burden doses are adjusted for this
decreased absorption at higher atmospheric concentra-
tions, potency estimates in the female rat and female
mouse are within a factor of three of each other, but
estimates based onthe malemouse are stillbetween one
to two orders ofmagnitude greater than those based on
the male rat.
Using the linearized multistage model to extrapolate
from the cancer response in the NTP mouse bioassay
(13), a correction factor for early termination, and the
estimatesofbodyburdenbasedonthedataofBondetal.
(24), the upper-limit incremental estimate of carcino-
genic potency for humans, assuming a 70-year contin-
uous exposure, is 2.5 x 10-1 per ppm. This means that
if a person were exposed to 1 ppm for 70 years, the
increased probability ofgetting cancer is not likely to
exceed 2.5 chances in 10. This estimate ofpotency is
decreased from the 6.4 x 10-1 per ppm unit risk esti-
mate published in 1985 (14).
Exposure Assessment
The third element in a risk assessment is the evalu-
ationofexposure. Inthis case, the evaluationfocuses on
exposure of people living near 1,3-butadiene-emitting
facilities. Exposure assessment, as was performed for
thisassessment, requirestwosteps: 1)identificationand
characterization ofthe sources and their emissions and
2) use of available data from step 1 in a computerized
model ofair dispersion. This model produces estimates
of1,3-butadieneconcentrationsinairandthenumbersof
people exposed to these estimates of concentration.
TheUnited Statesproduction of1,3-butadiene in 1987
was approximately 3 billion pounds annually (1) and
substantial amounts are imported. Annual emissions
from all industrial 1,3-butadiene sources are estimated
to be approximately 12 million pounds per year. These
emissions arise primarily from process vents or stacks
and fugitive sources (e.g., equipment leaks). Source
characterization data has been provided by industry in
response to EPA's request for information under the
authorityofSection 114oftheCleanAirAct. Thesedata
and engineeringjudgment have been used to character-
ize the sources. Types and amounts ofemissions, num-
bers of stacks, release temperatures, and velocity are
parameters that affect the estimates of air dispersion
and are inputs to the exposure modeling.
The Human Exposure Model (HEM) was used to
estimate exposure to 1,3-butadiene emissions (27). The
term "exposure" means the sum of the products of the
estimated ambient air concentration of 1,3-butadiene
and the estimated numbers ofpeople exposed to those
concentrations. A Gaussian dispersion model contained
within the HEM was employed to estimate ambient
concentrations of1,3-butadienewithin a50-kmradius of
specific emission sources. Exposure estimates are lim-
ited to 50 km because it is felt that the dispersion algo-
rithm is most accurate within this distance. Exposure
may occur at distances greater than 50 km, but the
half-life of 1,3-butadiene has been estimated to be rela-
tively brief-approximately 4 hr. While the half-life is
sufficient to allow for a 50-km dispersion, there is ex-
pected to be minimal impact on populations living at
greater distances. This is in contrast to pollutants with
long half-lives (e.g., carbon tetrachloride, cadmium)
where impact on populations beyond 50 km may be
substantial.
An additional input to the HEM modeling is a 5-year
average ofweather from the National Weather Service
station closest to each facility. Wind speed, direction,
and turbulence are important in the air dispersion mod-
eling. By combining population and estimated ambient
air concentrations, the HEM produced estimates ofex-
posure at selected radial distances from each identified
source and summed the exposure estimates for each
source.
Approximately 52 million people are estimated to live
within 50 km ofindustrial 1,3-butadiene sources. Each
plantwasmodeled without consideration ofother plants
that may be within the 50-km radius. Modeling each
plant separately, as was done here, may somewhat
underestimate the intensity of exposure and over-
estimate the total number of exposed individuals in
areas where more than one plant exists.
There are little ambient monitoring data available for
1,3-butadiene. Reported monitoring data range from
less than 1 to 10 ppb in urban air (28,29). The modeled
exposure concentrations appears to be consistent with
monitored off-site concentrations. Modeled estimates of
fenceline concentrations and occupational monitoring of
fenceline concentrations are also similar (30,31).
Risk Characterization
By combining the estimates of public exposure to
emissions of 1,3-butadiene from point sources with the
unit risk for 1,3-butadiene, two types of quantitative
estimates of the risk to public health have been pro-
duced. The first type ofrisk estimate, called aggregate
cancer incidence, is characterized as the excess number
ofcancers predicted to occur in the exposed population.
Thisisthesummationofallthecancerrisksestimatedby
combiningtheproductsofthepredictedambientconcen-
trations of 1,3-butadiene and the estimated number of
people exposed to those concentrations. The aggregate
incidence is expressed as incidences ofcancer among all
of the exposed population after 70 years of continuous
exposure; for convenience, it is often divided by 70 and
expressed as annual cancer incidence.
The second type of risk estimate, called "maximum
individual risk," is the estimated upper bound excess
cancer risk predicted for the individual(s) exposed con-
tinuallyfor70yearstothehighestestimatedambientair
concentration.
No more than 8 annual cancer incidences, or no more
than 560 cancer incidences per 70 years, nationwide are
currently being estimated to result from nonoccupa-
tional exposure to concentrations of 1,3-butadiene from
industrial emissions. Risk to the most exposed persons
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are not expected to be greater than one in ten. These
estimates are based on the upper 95% limit unit risk
estimate and the results ofthe HEM exposure modeling
analysis. A significant amount of uncertainty exists in
the estimates of maximum individual cancer risk and
annual cancer incidence. Sources of uncertainty in the
riskassessmentincludespeciesdifferences insensitivity
to 1,3-butadiene, the adequacy ofthe source character-
ization, the dose-response model used to perform low-
dose extrapolation and estimate potency, and the air
dispersion modeling and exposure. Reducing these un-
certainties with better data could either raise or lower
the current estimates of risk.
Conclusions
The EPA has concluded that air exposure fromindus-
trial emissions of 1,3-butadiene increases the risk of
cancer in the exposed population. This is based on the
weight of evidence of carcinogenicity, the estimate of
cancerpotency, thequantityofemissions, theestimated
ambient air concentrations, and the proximity of large
populations to emitting sources.
The estimate presented in this paper ofexcess cancer
cases resulting from point source exposure to 1,3-
butadiene is decreased to approximately 40% of the
estimatepublished in 1985(32), from6.4chancesin 10to
2.5 chances in 10 to lifetime exposure to 1 ppm. The
current estimate is no more thaneightadditional annual
cancer incidences in the general population. Increased
risktothe most exposedindividualsisnot anticipated to
be greater than one in ten. This reduction in the risk
estimate is due to a change in the estimate of 1,3-
butadiene potency (i.e., unit risk estimate) based on
incorporation of new pharmacokinetic data. The emis-
sions estimates, weight of evidence classification, and
estimates ofcancer potencypresented inthispapermay
change subsequent to the analysis of anticipated new
data.
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